Lexston Life Sciences Corp. (TSE:LEXT)
:LEXT
Want to see TSE:LEXT full AI Analyst Report?
LEXT Stock Chart & Stats
C$0.10
<C$0.01(11.11%)
At close: 4:00 PM EST
C$0.10
<C$0.01(11.11%)
Day’s Range― - ―
52-Week RangeC$0.06 - C$0.34
Previous CloseN/A
Volume1.00M
Average Volume (3M)40.70K
Market Cap
C$1.88M
Enterprise ValueC$273.67K
Total Cash (Recent Filing)C$278.52K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Sep 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding25,093,304
10 Day Avg. Volume77,591
30 Day Avg. Volume40,703
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)13.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / No Reported DebtA zero-debt capital structure materially reduces solvency and interest burdens, preserving strategic optionality. Over several months this provides durable flexibility to fund restructuring, R&D or commercialization via equity or partnerships rather than servicing debt, lowering bankruptcy risk.
Improving Cash-flow Trend (TTM)An improving free cash flow trend, even from negative levels, indicates the company may be stabilizing operations or cutting outflows. If sustained over 2–6 months, this reduces near-term financing pressure, lengthens runway and increases the chance management can execute a durable turnaround.
Historical Revenue And Gross ProfitPast revenue and positive gross profit show the business has previously achieved commercial traction and basic unit economics. That historical capability suggests assets, IP or customer relationships exist that management could redeploy to rebuild a revenue base over multiple months.
Bears Say
Zero Recent RevenueSustained absence of revenue is a structural weakness: without sales the firm cannot self-fund operations or prove market demand. Over a multi-month horizon this erodes competitive position, hampers customer retention, and forces reliance on external financing or asset monetization.
Persistent Negative Operating Cash FlowConsistent operating cash deficits indicate ongoing cash burn that shortens runway and increases dilution risk from financing. Structurally, negative OCF impedes reinvestment in growth, undermines supplier and partner confidence, and forces difficult trade-offs across strategy and capital allocation.
Negative Returns And Volatile EquityConsistently negative ROE and volatile equity reflect an inability to create shareholder value and unstable capitalization. Over months this signals weakened governance or execution, making it harder to attract long-term investors and raising the probability of dilutive recapitalizations.
Lexston Life Sciences Corp. News
LEXT FAQ
What was Lexston Life Sciences Corp.’s price range in the past 12 months?
Lexston Life Sciences Corp. lowest stock price was C$0.06 and its highest was C$0.34 in the past 12 months.
What is Lexston Life Sciences Corp.’s market cap?
Lexston Life Sciences Corp.’s market cap is C$1.88M.
When is Lexston Life Sciences Corp.’s upcoming earnings report date?
Lexston Life Sciences Corp.’s upcoming earnings report date is Sep 21, 2026 which is in 143 days.
How were Lexston Life Sciences Corp.’s earnings last quarter?
Lexston Life Sciences Corp. released its earnings results on Apr 03, 2026. The company reported -C$0.016 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.016.
Is Lexston Life Sciences Corp. overvalued?
According to Wall Street analysts Lexston Life Sciences Corp.’s price is currently Overvalued.
Does Lexston Life Sciences Corp. pay dividends?
Lexston Life Sciences Corp. does not currently pay dividends.
What is Lexston Life Sciences Corp.’s EPS estimate?
Lexston Life Sciences Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lexston Life Sciences Corp. have?
Lexston Life Sciences Corp. has 25,093,304 shares outstanding.
What happened to Lexston Life Sciences Corp.’s price movement after its last earnings report?
Lexston Life Sciences Corp. reported an EPS of -C$0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lexston Life Sciences Corp.?
Currently, no hedge funds are holding shares in TSE:LEXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Lexston Life Sciences Corp.
Lexston Life Sciences Corp. operates as a biotechnology company that provides cannabis testing and research services in Canada. The company also offers analytical testing for cannabis, pathogens, and toxins. In addition, it focuses on developing and validating methods for standardized manufacturing of plant derived psychedelics in the field of mental health and wellness. The company is based in Vancouver, Canada.
Technical Analysis
Options Prices
Currently, No data available
---